Chester Saldivar v. Fresenius Medical Care Holdings, Inc.

Case: 15-15497 Date Filed: 11/08/2016 Page: 1 of 19
[PUBLISH]
IN THE UNITED STATES COURT OF APPEALS
FOR THE ELEVENTH CIRCUIT
________________________
No. 15-15497
________________________
D.C. Docket No. 1:10-cv-01614-AT
UNITED STATES OF AMERICA EX REL.,
CHESTER SALDIVAR,
Petitioner-Appellant,
versus
FRESENIUS MEDICAL CARE HOLDINGS, INC.,
d/b/a FRESENIUS MEDICAL CARE NORTH AMERICA,
Respondent-Appellee.
________________________
Appeal from the United States District Court
for the Northern District of Georgia
________________________
(November 8, 2016)
Before ED CARNES, Chief Judge, JORDAN, Circuit Judge, and LAMBERTH, *
District Judge.
ROYCE C. LAMBERTH, District Judge:
*
Honorable Royce C. Lamberth, United States District Judge for the District of
Columbia, sitting by designation.
Case: 15-15497 Date Filed: 11/08/2016 Page: 2 of 19
Relator Chester Saldivar appeals the district court’s order granting summary
judgment to defendant Fresenius Medical Care Holdings, Inc. (Fresenius). This
case is a qui tam action arising under the False Claims Act (FCA), 31 U.S.C. §§
3729–3733. This is an appeal of a final judgment pursuant to 28 U.S.C. § 1291.
Whether or not jurisdiction ultimately exists in this case is the focus of this
opinion.
I.
Fresenius is a provider of End Stage Renal Disease (ESRD) outpatient
services. As part of these services, Fresenius administers the drugs Epogen and
Zemplar, both of which are distributed in vials. These vials contain slightly more
of the drug than is indicated on the packaging, referred to as “overfill.” In the
course of providing its services, Fresenius administered this overfill to patients,
and sought and received reimbursement for such overfill from the Centers for
Medicare and Medicaid Services (CMS).
Relator, Chester Saldivar, filed the instant qui tam action claiming Fresenius
violated the FCA by billing the government for overfill that it received for no
cost—allegedly a violation of the statutes governing CMS billing. See U.S. ex rel.
Saldivar v. Fresenius Med. Care Holdings, Inc., 972 F. Supp. 2d 1339, 1348 (N.D.
Ga. 2013) (Saldivar I). Saldivar filed suit in the United States District Court for
2
Case: 15-15497 Date Filed: 11/08/2016 Page: 3 of 19
the Northern District of Georgia in 2010. In March 2011, the Government
declined to intervene in this case, its right under the FCA. 31 U.S.C. § 3730(b).
Fresenius maintained that the action should be dismissed for lack of subject
matter jurisdiction due to the Public Disclosure Bar in the FCA, an argument they
raised—unsuccessfully—twice. U.S. ex rel. Saldivar v. Fresenius Med. Care
Holdings, Inc., 157 F. Supp. 3d 1311, 1313 (N.D. Ga. 2015). The Public
Disclosure Bar prevents qui tam actions if the allegations in question were publicly
disclosed. 31 U.S.C. § 3730(e)(4). In determining there was jurisdiction under §
3730(e)(4), the district court concluded that while Saldivar’s allegations of overfill
billing were publicly disclosed and the disclosed information was the basis of
Saldivar’s suit, Saldivar was an “original source” under § 3730(e)(4)(B) and was
thus not barred from bringing this action. 157 F. Supp. 3d at 1317-1325.
Specifically, Saldivar alleged improper billing for overfill based on his
personal experience tracking the use of overfill along with conversations he had
with other Fresenius employees and his knowledge of corporate policies. The
district court found that Saldivar’s allegations—that Fresenius was not just using,
but billing, for overfill—had been disclosed to the government through several
communications between Fresenius and CMS as well as publicly disclosed through
a complaint in another case. Id. at 1318–1321. Moreover, the district court held
that given our precedent on the issue, the disclosed information was the basis of
3
Case: 15-15497 Date Filed: 11/08/2016 Page: 4 of 19
Saldivar’s suit. Id. at 1321–1323. However, the district court found that Saldivar
was an original source based on (a) his experience ordering and otherwise
managing inventory for Zemplar and Epogen, (b) discussions with supervisors and
coworkers about overfill use and billing, and (c) his familiarity with Fresenius
corporate policies and clinic rankings that factored in the use of overfill. Id. at
1323–1326.
The proceedings were bifurcated and the parties filed motions for summary
judgment on multiple distinct issues. The parties first filed motions for summary
judgment on the questions of (a) if submission of claims for free overfill violated
the Medicare Act and (b) if it was thus a false claim. The district court found that
the submissions did violate the Medicare Act and were, as a result, false claims.
Saldivar I. Next, the parties filed motions for summary judgment on the question
of whether Fresenius’s actions met the intent requirement under the FCA: that the
party “knowingly” take an action. 31 U.S.C. § 3729; U.S. ex rel. Saldivar v.
Fresenius Med. Care Holdings, Inc., 145 F. Supp. 3d 1220 (N.D. Ga. 2015)
(Saldivar II). The court found that Fresenius’s actions did not meet the intent
requirement and thus granted its motion for summary judgment. Saldivar II.
Saldivar appeals that decision to this Court and, in its briefing, Fresenius argues
again that there is no jurisdiction due to the public disclosure bar.
4
Case: 15-15497 Date Filed: 11/08/2016 Page: 5 of 19
II.
In 2007, Saldivar started working at Fresenius as an equipment technician
for two clinics, where he later became the chief technician. As an equipment
technician, Saldivar repaired dialysis machines and completed other tasks as
directed, including placing orders for Epogen and Zemplar. In addition to ordering
the drugs, Saldivar was asked to report the “Zemplar analysis” which included an
inventory form. Saldivar would input the vial count at the beginning and end of
the month as well as the dosages administered. The form then automatically
calculated and displayed the amount of overfill utilized throughout the month. In
2009, Saldivar began inventorying Epogen as well, though he was only responsible
for inputting the vial counts—others entered the doses administered throughout the
month.
With respect to these inventory forms, Saldivar was told the forms were of
particular importance because they were the basis for billing medicare. Indeed,
conversations about overfill and billing seem to have been fairly common.
Saldivar stated that Fresenius employees talked about the company’s overfill
policy in meetings, in one-on-one conversations with managers, and in monthly as
well as quarterly reports.
5
Case: 15-15497 Date Filed: 11/08/2016 Page: 6 of 19
Despite being told about overfill billing and the relationship between his
inventory forms and billing, Saldivar was not himself directly involved in billing.
At his deposition, when asked if the inventory forms he filled out were provided to
the government for billing purposes, he responded, “I have no idea. I’m pretty sure
they filled out a different form for reimbursement.” When asked if he had any
facts, other than what he was told by managers, to suggest the inventory forms
were used as the basis for billing he responded, “No. I just go by what my
managers told me.” At multiple points when asked about billing practices he
responded that he “was not in the billing department.”
Starting before Saldivar was ever hired, overfill was the subject of much
discussion. Indeed, a July 2008 BNA article in “Pharmaceutical Law & Industry
Report” stated that the use of overfill was “certainly not a secret,” that Fresenius
had publicly acknowledged its utilization—including in a disclosure to the
Securities and Exchange Commission (SEC), and that overfill had been discussed
in two Office of the Inspector General (OIG) reports. Fresenius was also in
communication with the OIG about its overfill practices due to a “corporate
integrity agreement” between Fresenius and the OIG which was in place from
2000 to 2008. During a deposition with an official from CMS, Fresenius asked
specifically about CMS’s knowledge of Fresenius’ overfill practices. Specifically,
Fresenius asked, “throughout the time period of 2000 to 2010 CMS was aware that
6
Case: 15-15497 Date Filed: 11/08/2016 Page: 7 of 19
outpatient dialysis facilities were administering and billing for overfill for Epogen
and Zemplar, right?” to which the CMS official responded “Yes.” Fresenius later
asked “there’s simply no question that Fresenius fully disclosed to you that it was
using and billing for Zemplar and Epo overfill, right?” Response: “they did
disclose that to me, yes.” That same official later stated he “wasn’t aware of any
CMS policy that prohibited the use of billing overfill,” that he was under the
impression Fresenius had been and still was billing for overfill as of March 2007,
and that Fresenius “disclose[d] to [him] that they were using and billing for overfill
Epogen and Zemplar.”
Complicating the facts of this case is the 2003 passage of the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). MMA,
Pub. L. 108–173, 117 Stat. 2066 (codified in scattered sections of 42 U.S.C. and 26
U.S.C.). As part of this act, Zemplar and Epogen reimbursement were calculated
by the “Average Sales Price” (ASP) beginning in 2006. In 2010, CMS announced
a proposed rule, to be effective January 1, 2011, which “clarified” that billing for
ESRD overfill drugs was improper under ASP. Saldivar thus argues that the
operative question is Fresenius’s behavior and disclosures after ASP
reimbursement went into effect in 2006.
III.
7
Case: 15-15497 Date Filed: 11/08/2016 Page: 8 of 19
We review a district court order granting summary judgment de novo,
viewing the evidence and all reasonable inferences drawn from it in the light most
favorable to the nonmoving party. Battle v. Bd. of Regents for Ga., 468 F.3d 755,
759 (11th Cir. 2006). However, “to survive summary judgment, the nonmoving
party must offer more than a mere scintilla of evidence for its position; indeed, the
nonmoving party must make a showing sufficient to permit the jury to reasonably
find on its behalf.” Urquilla-Diaz v. Kaplan Univ., 780 F.3d 1039, 1050 (11th Cir.
2015). Additionally, “[a]s courts of limited jurisdiction, we are obliged to
‘scrupulously confine [our] own jurisdiction to the precise limits which the statute
has defined.’” Underwriters at Lloyd’s, London v. Osting-Schwinn, 613 F.3d
1079, 1086 (11th Cir. 2010) (quoting Healy v. Ratta, 292 U.S. 263, 270 (1934)).
As with summary judgment, we review a district court’s ruling on questions of
jurisdiction de novo, Holston Investments, Inc. B.V.I. v. LanLogistics Corp., 677
F.3d 1068, 1070 (11th Cir. 2012), with the burden of establishing jurisdiction
being on the party bringing the claim, Sweet Pea Marine, Ltd. v. APJ Marine, Inc.,
411 F.3d 1242, 1247 (11th Cir. 2005).
At the time of the underlying events in this case, the FCA read, in pertinent
part:
(A) No court shall have jurisdiction over an action under this section
based upon the public disclosure of allegations or transactions in a
criminal, civil, or administrative hearing, in a congressional,
8
Case: 15-15497 Date Filed: 11/08/2016 Page: 9 of 19
administrative, or Government Accounting Office report, hearing,
audit, or investigation, or from the news media, unless the action is
brought by the Attorney General or the person bringing the action is
an original source of the information.
(B) For purposes of this paragraph, “original source” means an
individual who has direct and independent knowledge of the
information on which the allegations are based and has voluntarily
provided the information to the Government before filing an action
under this section which is based on the information.
31 U.S.C. § 3730(e)(4)(A)-(B) (2006).1 This Court uses a three-part inquiry to
determine if jurisdiction exists under 31 U.S.C. § 3730(e): “(1) have the allegations
1
This section was amended in 2010. The district court found that the old version of the statute
applied in this case, citing Graham Cty. Soil & Water Conservation Dist. v. U.S. ex rel. Wilson,
559 U.S. 280, 283 (2010). Neither party has challenged that ruling. But because the pre-2010
version of the public disclosure bar was jurisdictional and subject matter jurisdiction cannot be
created by waiver or forfeiture, we must determine for ourselves whether the district court was
correct. See In re Bayou Shores SNF, LLC, 828 F.3d 1297, 1328 (11th Cir. 2016) (“When the
lower court lacks jurisdiction, we have jurisdiction on appeal, not of the merits but merely for the
purpose of correcting the error of the lower court in entertaining the suit.”) (internal quotation
marks omitted).
“United States Supreme Court decisions . . . clearly indicat[e] that statutes that affect substantive,
vested rights—even when framed in jurisdictional terms—are still presumed to apply only
prospectively.” Johnson v. Conner, 754 F.3d 918, 921 (11th Cir. 2014). The 2010 amendments
to the public disclosure bar changed the scope of the public disclosure defense available to
Fresenius under the prior version of the False Claims Act. See United States ex rel. May v.
Purdue Pharma L.P., 737 F.3d 908, 914–19 (4th Cir. 2013). For that reason, we conclude that it
is not retroactive and that Fresenius’ conduct should be evaluated under the law as it existed at
the time Fresenius submitted its allegedly false claims.
As a result, we agree with the district court that the old version of the statute applies to the
portion of Saldivar’s claims arising from Fresenius’ billing before the March 23, 2010 effective
date of the 2010 amendments. See ex rel. May, 737 F.3d at 914–19. We do not imply any view
about whether the issues would be decided differently under the new version of the statute,
except to the extent stated in the next paragraph, below.
We need not decide what version of the statute applies to Fresenius’ post-March 23, 2010
conduct, because Saldivar does not have any viable claims arising from it. Saldivar was
9
Case: 15-15497 Date Filed: 11/08/2016 Page: 10 of 19
made by the plaintiff been publicly disclosed; (2) if so, is the disclosed information
the basis of the plaintiff’s suit; (3) if yes, is the plaintiff an ‘original source’ of that
information.” Cooper v. Blue Cross & Blue Shield of Fla., Inc., 19 F.3d 562, 565
n. 4 (11th Cir.1994).
As jurisdiction is a necessary prerequisite to addressing the merits, Capron
v. Van Noorden, 6 U.S. (2 Cranch) 126 (1804), the Court must begin its inquiry by
analyzing each part of the Cooper framework.
a. Have the allegations made by the plaintiff been publicly disclosed?
The district court correctly held that the allegations made had been publicly
disclosed. Fresenius maintains that its practices were publicly disclosed in a
number of different forums including articles, litigation, and directly to the
government through the “corporate integrity agreement.” As the district court
properly noted and as highlighted in deposition excerpts above, it is clear from the
record below that OIG was aware that Fresenius was billing for overfill. OIG
affirmed that they were aware of the practice generally and that Fresenius
specifically was billing for overfill. Indeed, OIG noted that Fresenius disclosed
terminated on December 18, 2009, so any knowledge he had about Fresenius’ billing after that
date must have been obtained secondhand or from public disclosures. And his independent
knowledge does not materially add to what was already in the public domain. As a result,
Saldivar is not an original source as to any of Fresenius’ post-March 23, 2010 conduct under
either version of the statute.
10
Case: 15-15497 Date Filed: 11/08/2016 Page: 11 of 19
overfill billing for both Zemplar and Epogen, the two drugs at issue in this case.
This information, albeit in a more limited form, made its way into public reports.
For example, the 2004 OIG report on Medicare Reimbursement for Existing End-
Stage Renal Disease Drugs stated “providers reported that they are able to lower
actual acquisition costs through the utilization of overfill.” Moreover, Fresenius
was identified in the previously mentioned July 2008 BNA article that discussed
the use and profitability of overfill. Geoffrey R. Kaiser, Overfill: A Drug Sample
in Sheep’s Clothing, PHARMACEUTICAL LAW & INDUSTRY REPORT, July 2008.
Fresenius has also noted that information was disclosed through an SEC filing and
through prior litigation.
While it is true the law changed with the passage of the MMA, Fresenius’
overfill billing was nonetheless disclosed through the avenues discussed above.
The fact that the 2011 rule “clarified” the billing procedure does not change this.
While sympathetic to the idea that a disclosure could grow stale due to an
intervening change in law, there were repeated disclosures in this case, both before
and after the passage of the MMA. 2 Moreover, the statute has no requirement that
2
Both Fresenius and the District Court note that CMS officials knew—due to the OIG
investigation—that Fresenius was billing for overfill between 2000 and 2010. We need not
reach the question of whether that alone is sufficient, see United States v. Chattanooga-Hamilton
Cty. Hosp. Auth., 782 F.3d 260 (6th Cir. 2015), given that there were a number of public
disclosures in this case.
11
Case: 15-15497 Date Filed: 11/08/2016 Page: 12 of 19
information be repeatedly or regularly disclosed. Finally, the fact that a new rule
was required to clarify ASP billing practices belies the argument Fresenius should
have offered some further disclosure. Accordingly, we agree with the district court
that the use and billing of overfill was publicly disclosed and decline to analyze
each instance of possible public disclosure.
b. Is the disclosed information the basis of the plaintiff’s suit?
The district court was likewise correct in holding that the disclosed
information is the basis of Saldivar’s suit. We have explained that the language of
the FCA “is most naturally read to preclude suits based in any part on publicly
disclosed information,” Cooper, 19 F.3d at 567, and that this second prong of the
inquiry is a “quick trigger to get to the more exacting original source inquiry,” id.
at 568 n. 10. Here, the claim is based on Fresenius billing Medicare for overfill it
received at no cost. The public disclosures reveal it was “no secret” Fresenius was
using and billing for overfill. Accordingly, the disclosed information is the basis
of the plaintiff’s suit.
c. Is plaintiff an original source of the information?
The third prong of the inquiry is whether plaintiff is an “original source,”
allowing for jurisdiction to exist even when the information has been disclosed.
The statute defines an original source as one who has “direct and independent
12
Case: 15-15497 Date Filed: 11/08/2016 Page: 13 of 19
knowledge of the information on which the allegations are based.” 31 U.S.C. §
3730(e)(4)(B) (2006). Here, our holding differs from that of the district court,
which held that Saldivar was an original source of the information.
Two of our prior cases help guide our thinking. In Osheroff there was a
public disclosure that clinics were providing certain free services. U.S. ex rel.
Osheroff v. Humana Inc., 776 F.3d 805 (11th Cir. 2015). Relator, who was not an
employee of one of clinics in question, conducted his own investigation into the
value of the services being provided. Id. at 808. We held plaintiff was not an
original source as “background information that helps one understand or
contextualize a public disclosure is insufficient to grant original source status.” Id.
at 815.
Conversely, in Cooper there was widespread disclosure of fraud associated
with Medicare Secondary Provider (MSP) laws though none against the specific
defendant in question. 19 F.3d at 566. Relator filed suit after repeatedly informing
defendant of the regulations and then being sent back his claims with instructions
stating Medicare must pay first—a violation of MSP. Id. at 564. In holding relator
was an original source we cited with approval “it is not necessary for a relator to
have all the relevant information in order to qualify as ‘independent.’” Id. at 568
(citing and quoting U.S. ex rel. Stinson, Lyons, Gerlin & Bustamante, P.A. v.
Prudential Ins. Co., 944 F.2d 1149, 1160 (3d Cir. 1991)).
13
Case: 15-15497 Date Filed: 11/08/2016 Page: 14 of 19
In this case, Saldivar alleges that Fresenius improperly billed for Zemplar
and Epogen overfill. Saldivar was directly responsible for inventory sheets for
Zemplar and Epogen. He tracked beginning and end of month inventory, and in
the case of Zemplar, included the total dosage administered on his form. There is
no dispute that he had direct and independent knowledge of the administration of
overfill, as his inventory sheet automatically populated the overflow numbers.
Saldivar was also responsible for placing orders for Zemplar and Epogen as
inventory ran low. However, he stated he was not privy to price-related contracts
between Fresenius and the drug distributors, and his only firsthand interaction with
pricing appears to be seeing per-box prices on packing slips. With respect to billing
the government, both Saldivar and the district court highlight that Saldivar was told
that the “forms are the basis of billing Medicare.” Moreover, Saldivar had
discussions with coworkers about the use of overfill and was aware of corporate
policies and reports that rewarded clinics using overfill efficiently. Fresenius
claims Saldivar is not an original source because Saldivar’s knowledge of the
allegation—improper billing—was not direct and independent.
In order to show that a fraud has occurred, one generally must present a
submitted statement or claim (X) and the true set of facts (Y), which shows that X
is untrue. These two things together allow the conclusion (Z) that fraud has
occurred. See U.S. ex rel. Springfield Terminal Ry. Co. v. Quinn, 14 F.3d 645, 654
14
Case: 15-15497 Date Filed: 11/08/2016 Page: 15 of 19
(D.C. Cir. 1994). In this instance the false claim was the bill to the government.
However, the alleged true set of facts was not that overfill was administered, but
rather that Fresenius was obtaining drugs at no cost to themselves yet nonetheless
billing the government for those same drugs.3 Given that Saldivar’s firsthand
knowledge related to inventory and administration of overfill not costs and billing,
we now approach a question we have not explicitly addressed previously: whether
Saldivar’s secondhand knowledge is sufficient to make him an original source.
Several of our sister circuits have addressed this issue. The Tenth Circuit
has held that secondhand information is insufficient. In re Nat. Gas Royalties, 562
F.3d 1032, 1045–46 (10th Cir. 2009) (“We conclude that this secondhand
knowledge . . . does not constitute ‘direct and independent’ knowledge.”). It has
further explained that “to be independent, the relator's knowledge must not be
derivative of the information of others, even if those others may qualify as original
sources.” U.S. ex rel. Fine v. Advanced Scis., Inc., 99 F.3d 1000, 1007 (10th Cir.
1996). Likewise, the Eighth Circuit has held “a person who obtains secondhand
information from an individual who has direct knowledge of the alleged fraud does
not himself possess direct knowledge and therefore is not an original source under
3
For example, in his Statement of the Case Saldivar wrote: “In this False Claims Act (FCA)
case, the Relator Chester Saldivar, standing in the shoes of the United States, alleged that
Fresenius violated the FCA by billing the government for the overfill of injectable drugs it
received from manufacturers at no cost.” Saldivar’s brief does not argue that the use of overfill
was fraudulent.
15
Case: 15-15497 Date Filed: 11/08/2016 Page: 16 of 19
the Act.” U.S. ex rel. Barth v. Ridgedale Elec., Inc., 44 F.3d 699, 703 (8th Cir.
1995). The Eighth Circuit also took note of the False Claims Act legislative
history, which explained original sources as those who were “either close
observers or otherwise involved in the fraudulent activity.” Id. (citing S. Rep. No.
345, 99th Cong., 2d Sess. 4 (1986), reprinted in 1986 U.S.C.C.A.N. 5266, 5269.).
Similarly, the Third Circuit has stated that relators must have direct and
independent knowledge of the “most critical” elements of their claim and that
“[w]hile it is not necessary for a relator to have all the relevant information in order
to qualify as ‘independent,’ a relator cannot be said to have direct and independent
knowledge of the information on which [its fraud] allegations are based if the
relator has no direct and independent knowledge of the allegedly fraudulent
statements.” U.S. ex rel Mistick PBT v. Hous. Auth. of City of Pittsburgh, 186 F.3d
376, 389 (3d Cir. 1999) (internal citations omitted).
Finally, in Glaser v. Wound Care Consultants, Inc., plaintiff was a patient
who was treated several times by a physician’s assistant. 570 F.3d 907 (7th Cir.
2009). She filed an FCA claim alleging that defendant was overbilling Medicare
by having the physician’s assistants bill at the rate for doctors. Id. at 911. While
the case was extreme in that plaintiff had no knowledge at all of defendant’s billing
practices until contacted by a lawyer, the Seventh Circuit’s holding—that plaintiff
16
Case: 15-15497 Date Filed: 11/08/2016 Page: 17 of 19
needed to have direct and independent knowledge of the billing, not just the
treatment, id. at 921, is persuasive.
We find the reasoning of our sister circuits persuasive when reading the
statute. The phrase “direct and independent” is most naturally read as creating an
extreme limit on secondhand knowledge that is sufficient to qualify as an “original
source.” Being told what another department is doing is almost necessarily not
direct knowledge of that department’s behavior. In this case, Saldivar was told that
inventory spreadsheets were used for billing purposes. This is not direct
knowledge of the alleged improper billing. Indeed, it is on its face indirect; he was
told by another that his work product was used, and it appears he had no direct
knowledge of how billing occurred or even how his inventory was factored into the
billing.
In addition to being told his inventory was used for billing purposes,
Saldivar heard about overfill billing practices from others. This likewise is
indirect. Saldivar was the chief technician for two clinics, and while he appears to
have had a number of different tasks he stated multiple times that he was not in the
billing department and thus could not speak to many billing related practices. As
he himself attested, he went “by what [his] managers told [him].” This too is
attenuated, rather than direct, knowledge.
17
Case: 15-15497 Date Filed: 11/08/2016 Page: 18 of 19
Finally, Saldivar saw various reports that ranked or scored clinics, including
by their efficiency in utilizing overfill. The Court does not doubt that one could
easily infer from these, particularly when combined with what was being said by
managers and publicly disclosed, that Fresenius was charging for overfill.
However, to hold that merely reading a company’s quarterly reports grants direct
knowledge to the underlying activity would be to create a large aperture, rendering
the word “direct” in the statute near meaningless.
The FCA requires the Attorney General to investigate alleged violations. 31
U.S.C. § 3730(a). That is, the mere act of a relator filing under the FCA triggers
government action. To open the meaning of “direct” into something broader
would thus not only run contrary to the “cardinal” canon of construction that the
legislature “means in a statute what it says there,” Con. Nat. Bank v. Germain, 503
U.S. 249, 253–254 (1992), but potentially upset the Congressionally determined
balance between incentivizing qui tam suits on the one hand and flooding the
Department of Justice with required investigations on the other.
While Saldivar had independent knowledge of the administration of overfill,
his knowledge of the critical component—the alleged billing for drugs Fresenius
received at no cost—was derived from secondhand sources. To the extent
Saldivar’s information is not secondhand, it appears to be more akin to Osheroff’s
background information, e.g., what inventory forms looked like or how they were
18
Case: 15-15497 Date Filed: 11/08/2016 Page: 19 of 19
filled out, than the direct knowledge in Cooper. Saldivar thus fails to meet an
essential element of the original source requirement, that he have “direct and
independent knowledge of the information on which the allegations are based.” 31
U.S.C. § 3730(e)(4)(B) (2006) (emphasis added).
IV.
As we find that the allegations that are the basis of this complaint were
publicly disclosed and that Saldivar is not an original source, the Court lacks
jurisdiction to hear this case. We do not reach the merits of the motion for
summary judgment granted by the court below.
The district court’s grant of summary judgment on the merits is
REVERSED and the case is remanded for entry of an order dismissing the case
for lack of subject matter jurisdiction.
REVERSED AND REMANDED
19